Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth

Journal Article · 16 September 2021 · Frontiers in Immunology

DOI: https://doi.org/10.3389/fimmu.2021.734110 · OSTI ID:2470544

van Dorsten, Rebecca T. ^[1]; Wagh, Kshitij ^[2]; Moore, Penny L. ^[3]; Morris, Lynn ^[3]

---

1. National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg (South Africa); Univ. of the Witwatersrand, Johannesburg (South Africa)
2. Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
3. National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg (South Africa); Univ. of the Witwatersrand, Johannesburg (South Africa); Univ. of KwaZulu-Natal, Durban (South Africa)

Broadly neutralizing antibodies (bNAbs) are currently being assessed in clinical trials for their ability to prevent HIV infection. Single chain variable fragments (scFv) of bNAbs have advantages over full antibodies as their smaller size permits improved diffusion into mucosal tissues and facilitates vector-driven gene expression. We have previously shown that scFv of bNAbs individually retain significant breadth and potency. Here we tested combinations of five scFv derived from bNAbs CAP256-VRC26.25 (V2-apex), PGT121 (N332-supersite), 3BNC117 (CD4bs), 8ANC195 (gp120-gp41 interface) and 10E8v4 (MPER). Either two or three scFv were combined in equimolar amounts and tested in the TZM-bl neutralization assay against a multiclade panel of 17 viruses. Experimental IC₅₀ and IC₈₀ data were compared to predicted neutralization titers based on single scFv titers using the Loewe additive and the Bliss-Hill model. Like full-sized antibodies, combinations of scFv showed significantly improved potency and breadth compared to single scFv. Combinations of two or three scFv generally followed an independent action model for breadth and potency with no significant synergy or antagonism observed overall although some exceptions were noted. The Loewe model underestimated potency for some dual and triple combinations while the Bliss-Hill model was better at predicting IC₈₀ titers of triple combinations. Given this, we used the Bliss-Hill model to predict the coverage of scFv against a 45-virus panel at concentrations that correlated with protection in the AMP trials. Using IC₈₀ titers and concentrations of 1μg/mL, there was 93% coverage for one dual scFv combination (3BNC117+10E8v4), and 96% coverage for two of the triple combinations (CAP256.25+3BNC117+10E8v4 and PGT121+3BNC117+10E8v4). Combinations of scFv, therefore, show significantly improved breadth and potency over individual scFv and given their size advantage, have potential for use in passive immunization.

• Research Organization: Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
• Sponsoring Organization: USDOE
• Grant/Contract Number: 89233218CNA000001
• OSTI ID: 2470544
• Journal Information: Frontiers in Immunology, Journal Name: Frontiers in Immunology Vol. 12; ISSN 1664-3224
• Publisher: Frontiers Research FoundationCopyright Statement
• Country of Publication: United States
• Language: English